The bad news is that elevated CISD2 activity may be involved in tumorigenesis. Acting in its main function as a cytoprotector, CISD2 protects all cells indiscriminately from death, including cancer cells.
Thus, CISD2 activates the AKT/FOXO signaling pathway through AKT phosphorylation at Thr308 and Ser473.
AKT is known to be an important cell cycle mediator in oncogenesis, promoting proliferation and migration of cancer cells and resistance to apoptosis.
Also , CISD2 maintains normal mitochondrial function in degenerate cells, preventing elevated levels of iron and ROS (reactive oxygen species) from killing such a cell.
Therefore, manipulation of CISD2 , as with many similar genes, requires some kind of strong idea related to the suppression of tumorigenesis.
Maybe turn off telomerase or use some kind of cancer vaccine. For example, oncolytic viral immunotherapy, which acts exclusively on mutated cells, without affecting normal ones. Soon there will be material about this.
However…
The good news is that unlike, for example, epigenetic reprogramming, overexpression of CISD2 in animal models did not lead to negative effects associated with tissue transformation.
On the other hand, CISD2 may also act as a tumor-suppressing protein, depending on the stage or cell type involved in tumor development. So, in hepatocellular carcinoma, it has a protective effect, and its deficiency accelerates the pathological transformation of the tissue. Moreover, this has been described both in animal models and in humans.
Tellingly , the long-lived rodent Spalax , which is resistant to tissue degeneration, has a much higher expression of CISD2 in the liver compared to mice.
A similar dual role situation has been described with another cytoprotective protein, the heat shock protein Hsp90 .
The family of heat shock proteins performs the function of chaperones in the body, participating in folding (folding into the correct structure), degradation and stabilization of the protein, correcting errors in the protein structure. And, as is often the case, Hsp90 has a dual role in the body: useful and not very useful.
In addition to protecting vital proteins, Hsp90 supports proteins involved in carcinogenesis: it stabilizes several unstable oncogenic factors at once, such as mutant EGFR , BRAF and HER2 , as well as some anti-apoptotic factors, preventing the removal of degenerated cells.
That is, it turns out that going to the sauna is very useful, but only if you do not have cancer.
James Kickrland found senolytic properties in inhibitors of the Hsp90 protein (geldanamycin, tanespymycin, 17-DMAG, etc.). The mechanism by which Hsp90 inhibitors removed aged cells involved targeting an activated form of the protein kinase AKT. And it, in turn, suppresses apoptosis by affecting MTOR, NF-kB, Foxo3a and other signaling pathways in cancerous and old cells.
Introduction to transgenic mice with accelerated aging of one of the Hsp90 inhibitors, 17-DMAG, alleviated and delayed the onset of several age-related symptoms at once.
Note that the AKT signaling pathway appears in both cases: with Hsp90 and CISD2 proteins. Therefore, in order to combat age-related changes, it seems reasonable, along with CISD2 overexpression, to test in a laboratory experiment the effect of some senolytics that block the ACT pathway.
Or maybe the HSP90 also needs to be alternately activated and blocked.
In general, we suggest overexpressing and inhibiting the same thing in turn to try to add up the positive effects. It would be interesting to see what happens.
When creating Open Genes, we are pursuing the task so that any person with a natural science education can understand the genetics of aging and even be able to put forward their own hypothesis of what complex aging therapy might look like.
We want to systematize more information, so we are waiting for suggestions on how to improve everything. Come in and see how things are set up there.